UroGen Pharma Ltd.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
URGN$25.32-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flow
(unaudited; in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities | ||
| Net loss | $(127,130) | $(89,362) |
| Adjustment to reconcile net loss to net cash from operating activities: | ||
| Depreciation and amortization | 232 | 261 |
| Accrued financing on prepaid forward obligation | 1,595 | 9,013 |
| Accretion on marketable securities | (1,800) | (1,555) |
| Share-based compensation | 8,829 | 9,805 |
| Amortization (accretion) of discount on long-term debt | 377 | (1,330) |
| Amortization of right of use assets | 1,500 | 619 |
| Acquisitions of IPR&D | 3,128 | — |
| Changes in operating assets and liabilities: | ||
| Inventory | 886 | (1,921) |
| Accounts receivable, net | 599 | (7,359) |
| Prepaid expenses and other current assets | (3,277) | (3,772) |
| Other non-current assets | (6,170) | 1,668 |
| Accounts payable and accrued expenses | (1,258) | 3,147 |
| Employee related accrued expenses | 544 | (1,785) |
| Other current liabilities | (201) | — |
| Lease liabilities | (1,972) | (626) |
| Restricted deposit | (1) | 50 |
| Net cash used in operating activities | (124,119) | (83,147) |
| Cash Flows From Investing Activities | ||
| Purchases of marketable securities | (76,861) | (118,794) |
| Maturities of marketable securities | 110,974 | 37,740 |
| Purchases of property and equipment | (272) | (180) |
| Net cash provided by investing activities | 33,841 | (81,234) |
| Cash Flows From Financing Activities | ||
| Proceeds from exercise of options into ordinary shares | 629 | 250 |
| Proceeds from issuance of long-term debt | — | 24,488 |
| Proceeds from pre-funded warrant issuance, net of issuance costs | 3 | 18,641 |
| Proceeds from ordinary shares issuances, net of issuance costs | 7,970 | 151,169 |
| Net cash provided by financing activities | 8,602 | 194,548 |
| Increase (Decrease) in Cash and Cash Equivalents | (81,676) | 30,167 |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Period | 173,062 | 95,822 |
| Cash, Cash Equivalents and Restricted Cash at End of Period | $91,386 | $125,989 |
| Supplemental Disclosures of Non-Cash Activities | ||
| Right of use assets obtained in exchange for new operating lease liabilities | $6,856 | $— |
| Acquisitions of IPR&D | $3,128 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.